Compositions and methods for cancer imaging and radiotherapy
AssigneesVect-Horus, Centre National De La Recherche Scientifique, Universite D'Aix-Marseille
InventorsCédric Malicet, Pascaline Lecorche, Jonathan Nowak, Marion David, Jamal Temsamani, Michel Khrestchatisky
Life of this patent
Estimating the term…
Abstract
The present invention relates to a conjugated compound comprising a marker M pharmaceutically acceptable, and a peptide or pseudo-peptide P having at most 30 amino acid residues and able to bind the Low-Density Lipoprotein Receptor (LDLR) and to its use in a method of labelling and/or detecting and/or treating cancerous cells in a subject by administration of the conjugated compound to the subject an analysis of the presence and/or the amount of marker.
Claims8
A conjugated compound of formula M-C-P,
- wherein:
- M represents a pharmaceutically acceptable radionuclide,
- C represents a chelating cage forming a chelate with M, wherein said chelating cage is selected from:
- (i) DOTA and a functional derivative of DOTA,
- (ii) NODAGA and a functional derivative of NODAGA,
- (iii) NOTA and a functional derivative of NOTA,
- (iv) DOTA-GA and a functional derivative of DOTA-GA,
- wherein the functional derivative of DOTA, functional derivative of NODAGA, functional derivative of NOTA, or functional derivative of DOTA-GA is a compound in which one or more hydroxyl group is replaced by an amine group, and
- P represents a peptide or pseudo-peptide comprising an amino acid sequence selected from any one of SEQ ID NO:
- 1 to SEQ ID NO:
- 9, said peptide or pseudo-peptide having at most 30 amino acid residues and binding Low-Density Lipoprotein Receptor (LDLR).
Dependencies are inferred from the claim text.